Mazdutide vs Tirzepatide
| Attribute | Mazdutide IBI362, GLP-1/Glucagon dual agonist | Tirzepatide Dual GIP/GLP-1 receptor agonist |
|---|---|---|
| Category | Weight Loss & Metabolism | Weight Loss & Metabolism |
| Best known for | GLP-1/glucagon dual agonist weight-loss research | Dual-agonist weight loss research |
| In plain English | GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone. | Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies. |
| How it works | Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis). | Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying. |
| Researchers study | Obesity and metabolic-associated liver disease, particularly in Chinese clinical research. | Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes. |
| Internet discussion | Discussed alongside survodutide and retatrutide in next-gen metabolic research. | Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules. |
Mazdutide
GLP-1/glucagon dual agonist weight-loss research
GLP-1 reduces appetite; glucagon raises energy expenditure. Together they aim for more weight loss than GLP-1 alone.
Dual activation of GLP-1 receptors (satiety, insulin) and glucagon receptors (lipolysis, thermogenesis).
Obesity and metabolic-associated liver disease, particularly in Chinese clinical research.
Discussed alongside survodutide and retatrutide in next-gen metabolic research.
Mazdutide is a GLP-1/glucagon dual agonist researched for obesity and metabolic disease.
Tirzepatide
Dual-agonist weight loss research
Tirzepatide is like semaglutide with an extra lever pulled. It hits two appetite/insulin pathways at once, producing larger weight reduction in studies.
Co-activates GLP-1 and GIP receptors. GIP enhances insulin response and may help adipose tissue handle nutrients more efficiently while GLP-1 reduces appetite and slows gastric emptying.
Type 2 diabetes glycemic control, obesity, NASH/MASH, and cardiovascular outcomes.
Often described as 'semaglutide on steroids' for weight loss. Heavy discussion of side effect differences and titration schedules.
Tirzepatide is a dual GLP-1/GIP agonist with strong clinical data for weight reduction and glycemic control.